Abstract
The dismal prognosis of pancreatic cancer has motivated research into identifying non-invasive 'liquid biopsy' biomarkers for early detection when treatment is most effective. Recently, exosomes—nanoscale membranous vesicles shed from tumour cells and which can be found circulating in the blood (and most bodily fluids)—have been discovered to contain a wealth of proteomic and genetic information, showing promise for pre-symptomatic screening and monitoring of disease. Here we examine recent findings highlighting the diagnostic value of exosomes in pancreatic cancer as well as the emerging use of lab-on-a-chip (LOC) technologies aiming to streamline exosome isolation and analysis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.